SOVREMENNYE VOZMOZhNOSTI AD\"YuVANTNOY TERAPII VNEBOL'NIChNOY PNEVMONII
- Authors: Belevskiy A.S1
-
Affiliations:
- Issue: No 6 (2013)
- Pages: 49-52
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280507
- ID: 280507
Cite item
Open Access
Access granted
Abstract
Community-acquired pneumonia (CAP) is a serious medical problem, associated with a high mortality in some categories of patients. Antibacterial treatment of CAP is not always effective, primarily due to resistance of pathogens, which dictates the need for search of additional (adjuvant) treatment. The prospects for the use of glucocorticosteroids, drotrecogin alpha, granulocyte-colony stimulating factor, statins, angiotensin-converting enzyme inhibitors, N-acetylcysteine in CAP are considered. It is emphasized that although the adjuvant therapy does not substitute for antibiotics, it can improve the prognosis in a number of pathological conditions (such as acute respiratory distress syndrome).
Full Text
References
- Синопальников А.И. Внебольничная пневмония у взрослых // Consilium-medicum 2007. Т. 9. № 3.
- Rodrigez A, Lisboa T, Blot S, et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009;35(3):430-38.
- Huff J, White A, Power E, et al. 10-year trends in penicillin and erythromycin resistant S. pneumoniae for 5 European countries and the USA. The Alexander Project [abstract C2 1624]. In: Abstracts from the 42nd Interscience conference on antimicrobial agents and chemotherapy. San Diego, USA: American Society of Microbiology; 2002.
- Зубков М.Н. Современные проблемы резистентности пневмотропных патогенов // Пульмонология 2007. № 5. С. 5-13.
- Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000;46(suppl. T1):3-9.
- Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. Российское респираторное общество, МАКМАХ, М., 2010.
- Low D.E. Antimicrobial drug use and resistance among respiratory pathogens in the community.Clin Infect Dis 2002;33 (suppl. 3):S206-13.
- Richter SS, Brueggemann AB, Huynh HK, et al. A 1997-1999 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US Institutions. Int J Antimicrob Agents 1999;13:99-107.
- Angeles Marcos M, Camps M, Pumarola T, et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther 2006;11(3):351-59.
- Camps Serra M, Cervera C, Pumarola T, et.al. Virological diagnosis in community-acquired pneumonia in immunocompromised patients. Eur Respir J 2008;31(3):618-24.
- Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008;62:661-68.
- Salluh JI, Pvoa P, Soares M, et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008;12(3):R76.
- Авдеев С.Н. Осложнения внебольничной пневмонии. В кн: Пневмония / Под ред. А.Г. Чучалина, А.И. Синопальникова, Н.Е. Чернеховской. М., 2002. С. 134-81.
- Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care логических состояний (в частности, ОРДС) она может улучшать прогноз. В настоящее время продолжается поиск оптимальных адъювантных препаратов лечения ВП и режимов их дозирования. Med 2005;33:952-61.
- Nelson S, et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment hospitalized patients with community-acquired pneumonia. J Infect Dis1998;178(4):1075-80.
- Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003;31(2):367-73.
- Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005;6:82-8.
- Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Pulm Med 2005;13:12.
- Аляви А.Л., Курбанова Г.А. Состояние обмена оксида азота при включении N-ацетилцистеина в комплексную терапию больных внебольничной пневмонией // Проблемы туберкулеза и болезней легких 2007. № 9. С. 20-24.
- Авдеев С.Н., Батын С.З., Мержоева З.М., Чучалин А.Г. Высокие дозы N-ацетилцистеина при остром респираторном дистресс-синдроме // Пульмонология 2010. № 3.
Supplementary files
